HC Wainwright Reiterates Neutral Rating for Bolt Biotherapeutics (NASDAQ:BOLT)

HC Wainwright reaffirmed their neutral rating on shares of Bolt Biotherapeutics (NASDAQ:BOLT) in a report issued on Tuesday morning,Benzinga reports.

Separately, Stifel Nicolaus reduced their price target on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating for the company in a research report on Tuesday. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Stock Performance

NASDAQ:BOLT opened at $0.42 on Tuesday. Bolt Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.56. The business’s fifty day moving average is $0.47 and its 200 day moving average is $0.56. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The firm has a market cap of $16.07 million, a price-to-earnings ratio of -0.25 and a beta of 0.94.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.38). The firm had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.79 million. Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. Research analysts predict that Bolt Biotherapeutics will post -1.61 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. FMR LLC lifted its position in Bolt Biotherapeutics by 33.2% during the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the last quarter. Millennium Management LLC bought a new position in shares of Bolt Biotherapeutics in the 4th quarter worth $25,000. Squarepoint Ops LLC purchased a new stake in shares of Bolt Biotherapeutics during the 4th quarter valued at $26,000. Velan Capital Investment Management LP bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth $27,000. Finally, Citadel Advisors LLC purchased a new position in Bolt Biotherapeutics in the fourth quarter worth $42,000. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.